Mirabella Financial Services LLP Makes New $955,000 Investment in Johnson & Johnson (NYSE:JNJ)

Mirabella Financial Services LLP purchased a new stake in shares of Johnson & Johnson (NYSE:JNJ) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund purchased 6,606 shares of the company’s stock, valued at approximately $955,000.

A number of other large investors also recently modified their holdings of the stock. MetLife Investment Management LLC lifted its position in shares of Johnson & Johnson by 1.8% during the fourth quarter. MetLife Investment Management LLC now owns 637,349 shares of the company’s stock valued at $92,173,000 after purchasing an additional 11,299 shares in the last quarter. Natixis increased its position in shares of Johnson & Johnson by 16.4% during the fourth quarter. Natixis now owns 165,510 shares of the company’s stock valued at $23,936,000 after acquiring an additional 23,261 shares during the last quarter. Norinchukin Bank The increased its position in shares of Johnson & Johnson by 7.4% during the 4th quarter. Norinchukin Bank The now owns 117,460 shares of the company’s stock valued at $16,987,000 after purchasing an additional 8,049 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S grew its position in Johnson & Johnson by 16.3% during the fourth quarter. BI Asset Management Fondsmaeglerselskab A S now owns 382,088 shares of the company’s stock valued at $55,258,000 after buying an additional 53,677 shares during the period. Finally, Capital International Inc. CA increased its stake in shares of Johnson & Johnson by 18.2% during the 4th quarter. Capital International Inc. CA now owns 55,785 shares of the company’s stock worth $8,068,000 after purchasing an additional 8,588 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $157.42 on Monday. The company has a market capitalization of $379.37 billion, a P/E ratio of 23.67, a P/E/G ratio of 2.56 and a beta of 0.49. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The company has a fifty day moving average of $159.49 and a 200-day moving average of $154.95.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.59 by $0.18. The firm had revenue of $21.89 billion during the quarter, compared to analysts’ expectations of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. As a group, equities research analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be paid a $1.30 dividend. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.24. The ex-dividend date of this dividend is Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.30%. Johnson & Johnson’s dividend payout ratio is 74.59%.

Analysts Set New Price Targets

Several analysts have issued reports on JNJ shares. Argus upgraded Johnson & Johnson to a “strong-buy” rating in a research note on Friday, January 24th. Wells Fargo & Company dropped their price target on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 23rd. Bank of America cut their price target on Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating for the company in a report on Thursday, April 10th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 25th. Finally, Raymond James reduced their target price on Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating for the company in a report on Monday, April 14th. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $171.82.

Insider Activity at Johnson & Johnson

In other news, VP Robert J. Decker sold 6,999 shares of the business’s stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the sale, the vice president now owns 21,001 shares of the company’s stock, valued at approximately $3,483,645.88. The trade was a 25.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Timothy Schmid sold 403 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the sale, the executive vice president now owns 15,098 shares of the company’s stock, valued at $2,357,552.70. This represents a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is owned by insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.